$-0.11
(Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-52 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
68,527,296
10 Years Aggregate
CFO
$-441.67 Mln
EBITDA
$-507.76 Mln
Net Profit
$-520.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Otonomy (OTIC)
| -90.2 | -92.2 | -91.0 | -99.6 | -83.7 | -71.0 | -- |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Otonomy (OTIC)
| -95.8 | -67.9 | 68.9 | 107.0 | -66.5 | -65.1 | -42.7 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Otonomy (OTIC)
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II... clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Read more
-
Pres, CEO & Director
Dr. David Allen Weber
-
Pres, CEO & Director
Dr. David Allen Weber
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Otonomy (OTIC)
What is the current share price of Otonomy Inc (OTIC) Today?
The share price of Otonomy Inc (OTIC) is $0.01 (NASDAQ) as of 11-Apr-2023 15:59 EDT. Otonomy Inc (OTIC) has given a return of -83.66% in the last 3 years.
What is the current PB & PE ratio of Otonomy Inc (OTIC)?
Since, TTM earnings of Otonomy Inc (OTIC) is negative, P/E ratio is not available.
The P/B ratio of Otonomy Inc (OTIC) is 0.33 times as on 11-Apr-2023, a 94 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-2.67
|
-0.25
|
|
2020
|
-7.80
|
-0.67
|
|
2019
|
-2.82
|
-0.26
|
|
2018
|
-1.15
|
-0.14
|
|
2017
|
-1.87
|
1.44
|
What is the 52 Week High and Low of Otonomy Inc (OTIC)?
The 52-week high and low of Otonomy Inc (OTIC) are Rs -- and Rs -- as of 28-May-2026.
What is the market cap of Otonomy Inc (OTIC)?
Otonomy Inc (OTIC) has a market capitalisation of $ 1 Mln as on 11-Apr-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Otonomy Inc (OTIC)?
Before investing in Otonomy Inc (OTIC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.